Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Rating Reaffirmed by Cantor Fitzgerald
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report)‘s stock had its “neutral” rating reissued by analysts at Cantor Fitzgerald in a report released on Monday, Benzinga reports. They currently have a $150.00 price objective on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective indicates a potential downside of 39.42% from the stock’s current price. A number […]
More Stories
Tullow Oil (LON:TLW) Stock Price Down 7.6% After Analyst Downgrade
Tullow Oil plc (LON:TLW – Get Free Report) fell 7.6% during mid-day trading on Monday after Shore Capital lowered their...
Tullow Oil (LON:TLW) Stock Price Down 7.6% on Analyst Downgrade
Tullow Oil plc (LON:TLW – Get Free Report)’s stock price dropped 7.6% during trading on Monday after Shore Capital lowered...
Tullow Oil (LON:TLW) Shares Down 7.6% on Analyst Downgrade
Shares of Tullow Oil plc (LON:TLW – Get Free Report) traded down 7.6% on Monday after Shore Capital lowered their...
Head-To-Head Contrast: Avient (NYSE:AVNT) & ASP Isotopes (NASDAQ:ASPI)
Avient (NYSE:AVNT – Get Free Report) and ASP Isotopes (NASDAQ:ASPI – Get Free Report) are both basic materials companies, but...
Innoviva (NASDAQ:INVA) versus Roche (OTCMKTS:RHHBY) Head to Head Review
Innoviva (NASDAQ:INVA – Get Free Report) and Roche (OTCMKTS:RHHBY – Get Free Report) are both medical companies, but which is...
Intellia Therapeutics (NASDAQ:NTLA) Price Target Cut to $60.00 by Analysts at Chardan Capital
Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) had its price objective decreased by equities research analysts at Chardan Capital from...